Supplementary Fig 5 from Efficacy of Decitabine Plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy

Chunmeng Wang,Yang Liu,Dong Liang,Xiang Li,Qingming Yang,Malcolm V. Brock,Qian Mei,Jiejie Liu,Meixia Chen,Fang Shi,Miaomiao Liu,Jun Nie,Weidong Han

DOI: https://doi.org/10.1158/1078-0432.22479399.v1

2023-01-01

Abstract:Figure 5. PD-1 level in tumor-infiltrated T-cells.

What problem does this paper attempt to address?

Supplementary Fig 4 from Efficacy of Decitabine Plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy

Chunmeng Wang,Yang Liu,Dong Liang,Xiang Li,Qingming Yang,Malcolm V. Brock,Qian Mei,Jiejie Liu,Meixia Chen,Fang Shi,Miaomiao Liu,Jun Nie,Weidong Han

DOI: https://doi.org/10.1158/1078-0432.22479402

2023-01-01

Abstract:Figure 4. Ratio of peripheral central memory T-cells and association with progression-free survival.
Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy

Chunmeng Wang,Yang Liu,Liang Dong,Xiang Li,Qingming Yang,Malcolm V. Brock,Qian Mei,Jiejie Liu,Meixia Chen,Fengxia Shi,Miao Liu,Jing Nie,Weidong Han

DOI: https://doi.org/10.1158/1078-0432.CCR-21-0133

IF: 13.801

2021-05-15

Clinical Cancer Research

Abstract:Purpose: Programmed death-1 (PD-1) blockade monotherapy is effective in relapsed/refractory classical Hodgkin lymphoma (cHL), but a subset of patients is recalcitrant to PD-1 inhibitors and only a minority of patients achieves durable remission. Effective treatment regimens for those with relapsed/progressive cHL after single-agent anti-PD-1 are urgently needed. Anti-PD-1 combination with the DNA-demethylating agent decitabine showed positive preliminary results in our test cohort patients who were resistant to anti-PD-1. Here, we assess the efficacy of decitabine plus anti-PD-1 therapy in an expansion cohort and after longer follow-up. Patients and Methods: We present the response and progression-free survival rates from patients with relapsed/refractory cHL who relapsed/progressed after prior anti-PD-1 monotherapy, and who received decitabine (10 mg/day, days 1–5) plus the anti-PD-1 camrelizumab (200 mg, day 8), every 3 weeks in a phase II trial (ClinicalTrials.gov: NCT02961101 and NCT03250962). Results: Overall, 51 patients (test cohort: 25, expansion cohort: 26) were treated and 50 evaluated for efficacy. The objective response rate was 52% [nine complete responses (CR); 36%] in the test cohort, and 68% (six CRs; 24%) in the expansion cohort. Median progression-free survival with decitabine plus camrelizumab was 20.0 and 21.6 months, respectively, which was significantly longer than that achieved with prior anti-PD-1 monotherapy. Durable response was observed in an estimated 78% of patients who achieved CR at 24 months. After decitabine plus camrelizumab, the ratio increase of circulating peripheral central memory T cells directly correlated with both clinical response and progression-free survival. Conclusions: Decitabine plus camrelizumab is associated with high response rates and long-term benefits in patients with relapsed/refractory cHL who failed PD-1 inhibitors.

oncology
Supplementary Figure S2 from Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer

Jhanelle E. Gray,Andreas Saltos,Tawee Tanvetyanon,Eric B. Haura,Ben Creelan,Scott J. Antonia,Michael Shafique,Hong Zheng,Wenjie Dai,James J. Saller,Zhihua Chen,Nishan Tchekmedyian,Kristen Goas,Ram Thapa,Theresa A. Boyle,Dung-Tsa Chen,Amer A. Beg

DOI: https://doi.org/10.1158/1078-0432.22471758.v1

2023-01-01

Abstract:Approach to assess levels of monocytic and PMN MDSC in patient PBMCs.
Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma

Yang Liu,Chunmeng Wang,Xiang Li,Liang Dong,Qingming Yang,Meixia Chen,Fengxia Shi,Malcolm Brock,Miao Liu,Qian Mei,Jiejie Liu,Jing Nie,Weidong Han

DOI: https://doi.org/10.1136/jitc-2021-002347

IF: 12.469

2021-04-01

Journal for ImmunoTherapy of Cancer

Abstract:Background Programmed death-1 (PD-1) blockade monotherapy induced durable remission in a subset of patients with relapsed/refractory classical Hodgkin lymphoma (cHL). We asked whether the anti-PD-1 agent, camrelizumab, combined with the DNA demethylating agent, decitabine, improves progression-free survival (PFS) in patients with relapsed/refractory cHL over camrelizumab alone. Methods This extended follow-up of an ongoing randomized phase II trial analyzed PFS among patients enrolled from January 2017 through July 2018. Sixty-one patients with relapsed/refractory cHL who were clinically naïve to PD-1 blockade and had received ≥2 previous therapies were randomized 1:2 to receive either camrelizumab (200 mg) monotherapy or camrelizumab (200 mg, day 8) combined with decitabine (10 mg/day, days 1–5) every 3 weeks. Results With a median follow-up of 34.5 months, complete remission was 79% (95% CI 63% to 90%) in the decitabine-plus-camrelizumab group versus 32% (95% CI 13% to 57%) in the camrelizumab group (p=0.001). Median duration of response was not reached in the decitabine-plus-camrelizumab group, with an estimated 63% (95% CI 46% to 75%) of patients maintaining a response at 24 months. Median PFS with decitabine-plus-camrelizumab therapy was 35.0 months (95% CI not reached) and 15.5 months (95% CI 8.4 to 22.7 months) with camrelizumab monotherapy (HR, 0.46; 95% CI 0.21 to 1.01; p=0.02). Female gender, lower tumor burden, and fewer previous therapies were favorable prognostic factors for durable remission with camrelizumab monotherapy. The PFS benefits of decitabine-plus-camrelizumab versus camrelizumab were observed in most subgroups, especially in patients with relative larger tumor burdens and those treated with ≥3 prior therapies. After decitabine-plus-camrelizumab treatment, the percentage increase of circulating peripheral central memory T-cells correlated with both improved clinical response and PFS, suggesting a putative biomarker of decitabine-plus-camrelizumab therapy for cHL. Conclusions Decitabine-plus-camrelizumab results in longer PFS compared with camrelizumab alone in patients with relapsed/refractory cHL. Trial registration numbers NCT02961101 and NCT03250962 .

oncology,immunology
Supplementary Data 1 from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer

Tao Jiang,Qiqi Jin,Jiahao Wang,Fengying Wu,Jian Chen,Gongyan Chen,Yunchao Huang,Jianhua Chen,Ying Cheng,QiMing Wang,Yueyin Pan,Jianying Zhou,Jianhua Shi,Xingxiang Xu,LiZhu Lin,Wei Zhang,Yiping Zhang,Yunpeng Liu,Yong Fang,Jifeng Feng,Zhehai Wang,Sheng Hu,Jian Fang,Yongqian Shu,Jiuwei Cui,Yi Hu,Wenxiu Yao,Xingya Li,Xiaoyan Lin,Rui Wang,Yongsheng Wang,Wei Shi,Gaohua Feng,Jun Ni,Beibei Mao,Dandan Ren,Huaibo Sun,Henghui Zhang,Luonan Chen,Caicun Zhou,Shengxiang Ren

DOI: https://doi.org/10.1158/1078-0432.23791953.v1

2023-01-01

Abstract:Supplementary Materials
Figure S5 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Zhen Zhang,Xuan Zhao,Qitai Zhao,Xinfeng Chen,Congcong Li,Yaqing Liu,Chunyi Shen,Lijie Song,Lijun Miao,Fuyou Guo,Xiaoning Mou,Jie Zhao,Weiyue Gu,Yi Zhang

DOI: https://doi.org/10.1158/2326-6066.27951174

2024-01-01

Abstract:Supplementary Figure S5. Characterization of PD-1+ and PD-1- CD4+ T cells in PB and tumor.
Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Zhiliang Ma,Wen Li,Shinichi Yoshiya,Yong Xu,Masaki Hara,Yosif El‐Darawish,Tzvetanka Markova,Kyosuke Yamanishi,Hiromichi Yamanishi,Hideaki Tahara,Yoshimasa Tanaka,Haruki Okamura

DOI: https://doi.org/10.1158/1078-0432.22459815.v1

2023-01-01

Abstract:Cytotoxic activity exhibited by PECs from pre-implanted mice receiving immune checkpoint blockade and/or IL-18
Supplementary Data from PD-1 Blockade Boosts Radiofrequency Ablation–Elicited Adaptive Immune Responses Against Tumor

Liangrong Shi,Lujun Chen,Changping Wu,Yibei Zhu,Bin Xu,Xiao Zheng,Mingfen Sun,Wen,Xichao Dai,Min Yang,Quansheng Lv,Binfeng Lu,Jingting Jiang

DOI: https://doi.org/10.1158/1078-0432.22457843

2023-01-01

Abstract:Supplemental figure 1. Patient cohort and study design. Supplemental Figure 2. Immunochemical staining of PD-L1 antibody (1:500, clone: SP142) on the paraffin-embedded human melanoma and placenta tissues. Supplemental Figure 3. RFA of colorectal liver metastases increased PD-L1 expression on infiltrating immune cells. Supplemental Figure 4. Correlation between PD-L1 expression on tumor cells and the intensity of CD8+, CD4+ T cell infiltration in endoscopic biopsy (A, B) and resected tumor specimen (C, D) (all of 78 patients were included). Supplemental Figure 5. RFA increased CD45+ immune cells and T cells infiltrating into contralateral tumor. Supplemental Figure 6. RFA increased T cells infiltration and PD-1/PD-L1 expression in a disdant tumor in B16 tumor-bearing mice. Supplemental Figure 7. RFA did not upregulate PD-1/PD-L1 expression in splenic lymphocytes. Supplemental Figure 8. RFA increased Tim-3, CD160, CD244 and eomes expression in a disdant tumor in CT26 tumor-bearing mice. Supplemental Figure 9. RFA and the anti-PD-1 therapy increased CD8+TIL cell infiltration in distant tumor. Supplemental Figure 10. RFA and the anti-PD-1 therapy upregulated Tim-3 expression on T cells in a distant tumor. Supplemental Table 1 Primer sequences used for the detection of gene expression by RT-QPCR Supplemental Table 2 Patient characteristic Supplemental table 3. Multivariate analysis of factors related to increased PD-L1 expression in resected tumor specimen.
Supplementary Data from CD19-specific CAR T Cells That Express a PD-1/CD28 Chimeric Switch-Receptor Are Effective in Patients with PD-L1–positive B-Cell Lymphoma

Hui Liu,Wen Lei,Chaoting Zhang,Chunmei Yang,Juying Wei,Qunyi Guo,Xiaojun Guo,Zhilu Chen,Ying Lu,Ken H. Young,Zheming Lu,Wenbin Qian

DOI: https://doi.org/10.1158/1078-0432.23586761.v1

2023-01-01

Abstract:Supplementary Data from CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1–positive B-Cell Lymphoma
Supplementary Figure 6 from Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells Against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia

Yongxian Hu,Zhao Wu,Yi Luo,Jimin Shi,Jian Yu,Chengfei Pu,Zuyu Liang,Guoqing Wei,Qu Cui,Jie Sun,Jing Jiang,Jue Xie,Yamin Tan,Wanmao Ni,Jifang Tu,Jinping Wang,Aiyun Jin,Hao Zhang,Zhen Cai,Lei Xiao,He Huang

DOI: https://doi.org/10.1158/1078-0432.22462346.v1

2023-01-01

Abstract:The cumulative incidence of non-relapse mortality are shown.
Epigenetic Agents Plus Anti-Pd-1 Reshapes Tumor Microenvironment and Restores Antitumor Efficacy in Hodgkin Lymphoma

Jing Nie,Chunmeng Wang,Liangtao Zheng,Yang Liu,Chengcheng Wang,Yixin Chang,Yudi Hu,Bing Guo,Yuting Pan,Qingming Yang,Xueda Hu,Weidong Han

DOI: https://doi.org/10.1182/blood.2024024487

IF: 20.3

2024-01-01

Blood

Abstract:DNA methyltransferase inhibitor decitabine plus anti-PD-1 (DP) combination therapy was effective in relapsed/refractory classic Hodgkin lymphoma (cHL). However, a subset of patients experienced primary resistance or relapse/progression after DP therapy. In this study, we evaluated the efficacy and safety of a triplet regimen consisting of the histone deacetylase inhibitor chidamide, decitabine and anti-PD-1 camrelizumab (CDP) in 52 patients with relapsed/refractory cHL who had previously received DP therapy (NCT04233294). CDP treatment was well-tolerate and resulted in an objective response rate of 94% (95% CI, 84-99%), with 50% (95% CI, 36-64%) of patients achieving complete response (CR). Notably, all patients who were recalcitrant to previous DP treatment exhibited therapeutic responses following CDP therapy, although their CR rate was lower compared to patients responsive to prior DP. Overall, the median progression-free survival following CDP therapy was 29.4 months. Through single-cell RNA sequencing of pre-treatment and on-treatment cHL tumor biopsies, we observed the heterogeneity of rare malignant Hodgkin Reed/Sternberg (HRS)-like cells. The classical CD30+ HRS-like cells interacted with the abundant immunosuppressive IL21+CD4+ T helper cells, forming a positive feedback loop that supported their survival. In contrast, the CD30- HRS-like cell population showed potential resistance to anti-PD-1 immunotherapy. CDP treatment promoted the activation of diverse tumor-reactive CD8+ T cells and suppressed the proliferation of IL21+CD4+ T cells by inhibiting STAT1/3 signaling, thereby alleviating their immunosuppressive effects. These findings provide insights into the cHL microenvironment that contributes to anti-PD-1 resistance and highlight the therapeutic effectiveness of dual epi-immunotherapy in overcoming immunotherapy resistance.
Supplementary Figure S2 from Safety and Clinical Response to Combined Immunotherapy with Autologous Inkt Cells and PD-1+CD8+ T Cells in Patients Failing First-Line Chemotherapy in Stage IV Pancreatic Cancer

Jing Wang,Xiaobo Cheng,Yanling Jin,Bili Xia,Ran Qin,Wei Zhang,Huiliang Hu,Xiaoting Mao,Liting Zhou,Yan Jia,Xiaoyan Zhang,Jianqing Xu

DOI: https://doi.org/10.1158/2767-9764.23098887

2023-01-01

Abstract:Change of tumor markers recorded over time during treatment.
Supplementary Figure S4 from Safety and Clinical Response to Combined Immunotherapy with Autologous Inkt Cells and PD-1+CD8+ T Cells in Patients Failing First-Line Chemotherapy in Stage IV Pancreatic Cancer

Jing Wang,Xiaobo Cheng,Yanling Jin,Bili Xia,Ran Qin,Wei Zhang,Huiliang Hu,Xiaoting Mao,Liting Zhou,Jia Yan,Xiaoyan Zhang,Jianqing Xu

DOI: https://doi.org/10.1158/2767-9764.23098875.v1

2023-01-01

Abstract:Heatmap shows the frequencies of the top 50 TCR clones in CD8+T cells in cell products pre-infusion and PBMCs four weeks post infusion. Scale bar, %.
Supplementary Figure S1 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

Yuqin Song,Zhengming Jin,Zhi-Ming Li,Yanyan Liu,Lanfang Li,Chuan He,Hang Su,Hui Zhou,Kunyan Li,Siguo Hao,Xuelan Zuo,Jianyuan Wu,Dengju Li,Meng Wu,Xiuhua Sun,Junyuan Qi,Zhen Cai,Zengjun Li,Yijing Li,Yanhua Huang,Jie Shen,Zhenyu Xiao,Jun Zhu

DOI: https://doi.org/10.1158/1078-0432.25515657

2024-01-01

Abstract:Supplementary Figure S1. Progression-free survival by lymphoma subtype.
Figure S9 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Zhen Zhang,Xuan Zhao,Qitai Zhao,Xinfeng Chen,Congcong Li,Yaqing Liu,Chunyi Shen,Lijie Song,Lijun Miao,Fuyou Guo,Xiaoning Mou,Jie Zhao,Weiyue Gu,Yi Zhang

DOI: https://doi.org/10.1158/2326-6066.27951162

2024-01-01

Abstract:Supplementary Figure S9. The level of serum cytokines in patients after modified PD-1+ T cell therapy.
Figure S5 from Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy

Mingming Zhang,Linghui Zhou,Houli Zhao,Yanlei Zhang,Guoqing Wei,Ruimin Hong,Wenjun Wu,Huijun Xu,Linqin Wang,Fang Ni,Jiazhen Cui,Shuixiu Peng,Chih-Hua Huang,Alex H. Chang,Yongxian Hu,He Huang

DOI: https://doi.org/10.1158/1078-0432.24952270

2024-01-01

Abstract:Supplementary figure S5 Representative imaging observations before and after CAR-T therapy
Figure S8 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Zhen Zhang,Xuan Zhao,Qitai Zhao,Xinfeng Chen,Congcong Li,Yaqing Liu,Chunyi Shen,Lijie Song,Lijun Miao,Fuyou Guo,Xiaoning Mou,Jie Zhao,Weiyue Gu,Yi Zhang

DOI: https://doi.org/10.1158/2326-6066.27951165

2024-01-01

Abstract:Supplementary Figure S8. Levels of CAR-T cells and B cells in PB after cell infusion.
Figure S1 from Blocking CX3CR1+ Tumor-Associated Macrophages Enhances the Efficacy of Anti-PD1 Therapy in Hepatocellular Carcinoma

Xiaonan Xiang,Kai Wang,Hui Zhang,Haibo Mou,Zhixiong Shi,Yaoye Tao,Hongliang Song,Zhengxing Lian,Shuai Wang,Di Lu,Xuyong Wei,Haiyang Xie,Shusen Zheng,Jianguo Wang,Xiao Xu

DOI: https://doi.org/10.1158/2326-6066.27601685

2024-01-01

Abstract:Supplementary Figure S1. Flow cytometry and FACS gating strategy
Supplementary Data from Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response

Shilpak Chatterjee,Paramita Chakraborty,Anusara Daenthanasanmak,Supinya Iamsawat,Gabriela Andrejeva,Libia A. Luevano,Melissa Wolf,Uday Baliga,Carsten Krieg,Craig C. Beeson,Meenal Mehrotra,Elizabeth G. Hill,Jeffery C. Rathmell,Xue-Zhong Yu,Andrew S. Kraft,Shikhar Mehrotra

DOI: https://doi.org/10.1158/1078-0432.22469031

2023-01-01

Abstract:Supplementary Figures and Figure Legends
Figure S9 from Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells

Chien-Hsing Chang,Yang Wang,Rongxiu Li,Diane L. Rossi,Donglin Liu,Edmund A. Rossi,Thomas M. Cardillo,David M. Goldenberg

DOI: https://doi.org/10.1158/0008-5472.22414134.v1

2023-01-01

Abstract:. Effect of cPD-1 and T cells purified from PBMCs on single spheroids of MDA-MB-231 stimulated (A) or not (B) with IFN-gamma in the presence and absence of (E1)-3s

Supplementary Fig 5 from Efficacy of Decitabine Plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy

Supplementary Fig 4 from Efficacy of Decitabine Plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy

Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy

Supplementary Figure S2 from Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer

Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma

Supplementary Data 1 from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer

Figure S5 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Supplementary Data from PD-1 Blockade Boosts Radiofrequency Ablation–Elicited Adaptive Immune Responses Against Tumor

Supplementary Data from CD19-specific CAR T Cells That Express a PD-1/CD28 Chimeric Switch-Receptor Are Effective in Patients with PD-L1–positive B-Cell Lymphoma

Supplementary Figure 6 from Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells Against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia

Epigenetic Agents Plus Anti-Pd-1 Reshapes Tumor Microenvironment and Restores Antitumor Efficacy in Hodgkin Lymphoma

Supplementary Figure S2 from Safety and Clinical Response to Combined Immunotherapy with Autologous Inkt Cells and PD-1+CD8+ T Cells in Patients Failing First-Line Chemotherapy in Stage IV Pancreatic Cancer

Supplementary Figure S4 from Safety and Clinical Response to Combined Immunotherapy with Autologous Inkt Cells and PD-1+CD8+ T Cells in Patients Failing First-Line Chemotherapy in Stage IV Pancreatic Cancer

Supplementary Figure S1 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

Figure S9 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Figure S5 from Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy

Figure S8 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Figure S1 from Blocking CX3CR1+ Tumor-Associated Macrophages Enhances the Efficacy of Anti-PD1 Therapy in Hepatocellular Carcinoma

Supplementary Data from Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response

Figure S9 from Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells